Characterization of Alzheimer's disease-like neuropathology in Duchenne's muscular dystrophy using the DBA/2J mdx mouse model.
Alzheimer's disease
Duchenne muscular dystrophy
amyloid
brain
cognition
muscular dystrophy
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
28
09
2021
received:
27
01
2021
accepted:
19
10
2021
pubmed:
21
10
2021
medline:
1
4
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder caused by a mutation in the dystrophin gene. In addition to muscle pathology, some patients with DMD will exhibit cognitive impairments with severity being linked to age and type of genetic mutation. Likewise, some studies have shown that mdx mice display impairments in spatial memory compared with wild-type (WT) controls, while others have not observed any such effect. Most studies have utilized the traditional C57BL/10 (C57) mdx mouse, which exhibits a mild disease phenotype. Recently, the DBA/2J (D2) mdx mouse has emerged as a more severe and perhaps clinically relevant DMD model; however, studies examining cognitive function in these mice are limited. Thus, in this study we examined cognitive function in age-matched C57 and D2 mdx mice along with their respective WT controls. Our findings show that 8- to 12-week-old C57 mdx mice did not display any differences in exploration time when challenged with a novel object recognition test. Conversely, age-matched D2 mdx mice spent less time exploring objects in total as a well as less time exploring the novel object, suggestive of impaired recognition memory. Biochemical analyses of the D2 mdx brain revealed higher soluble amyloid precursor protein β (APPβ) and APP in the prefrontal cortex of mdx mice compared with WT, and lower soluble APPα in the hippocampus, suggestive of a shift towards amyloidogenesis and a similar pathogenesis to Alzheimer's disease. Furthermore, our study demonstrates the utility of the D2 mdx model in studying cognitive impairment.
Identifiants
pubmed: 34668666
doi: 10.1002/2211-5463.13317
pmc: PMC8727939
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-162Informations de copyright
© 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Nature. 1997 Aug 28;388(6645):878-81
pubmed: 9278049
FASEB J. 2019 Jul;33(7):8110-8124
pubmed: 30933664
J Int Neuropsychol Soc. 2008 Sep;14(5):853-61
pubmed: 18764980
Hum Mol Genet. 2006 May 1;15(9):1437-49
pubmed: 16551656
Arch Dis Child. 1980 Aug;55(8):589-94
pubmed: 7436514
Sci Rep. 2017 Oct 3;7(1):12575
pubmed: 28974727
Muscle Nerve. 2002 Oct;26(4):506-12
pubmed: 12362416
Neurobiol Learn Mem. 2015 Oct;124:111-22
pubmed: 26190833
Acta Myol. 2014 May;33(1):13-8
pubmed: 24843230
Dev Med Child Neurol. 1988 Jun;30(3):316-27
pubmed: 3402673
Brain Res. 2010 Oct 21;1357:175-83
pubmed: 20713025
Neuroscience. 1999;93(4):1409-20
pubmed: 10501466
Nature. 1990 Dec 20-27;348(6303):725-8
pubmed: 2259381
J Neurophysiol. 2016 Sep 1;116(3):1304-15
pubmed: 27385793
Dev Med Child Neurol. 2007 Feb;49(2):123-8
pubmed: 17254000
Lancet. 2002 Feb 23;359(9307):687-95
pubmed: 11879882
Sci Rep. 2020 Aug 21;10(1):14070
pubmed: 32826942
Nat Protoc. 2013 Dec;8(12):2531-7
pubmed: 24263092
Exp Cell Res. 2015 May 15;334(1):45-53
pubmed: 25573596
J Neuromuscul Dis. 2016 Mar 3;3(1):29-48
pubmed: 27854202
Mol Neurobiol. 2019 Nov;56(11):7608-7616
pubmed: 31077034
Neuromuscul Disord. 2013 Jun;23(6):451-5
pubmed: 23535446
PLoS One. 2010 Jan 20;5(1):e8803
pubmed: 20098710
Front Behav Neurosci. 2021 Jan 20;14:629043
pubmed: 33551769
Biomark Res. 2017 Sep 22;5:28
pubmed: 29018524
J Bone Miner Res. 2011 Aug;26(8):1891-903
pubmed: 21509823
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
FEBS Open Bio. 2022 Jan;12(1):154-162
pubmed: 34668666
J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):715-21
pubmed: 19258354
Neuromuscul Disord. 1992;2(5-6):371-8
pubmed: 1300185
Hum Mol Genet. 2016 Jan 1;25(1):130-45
pubmed: 26566673
Nat Med. 2008 Aug;14(8):837-42
pubmed: 18568035
J Alzheimers Dis. 2010;19(1):311-23
pubmed: 20061647
FASEB J. 2008 Jan;22(1):246-60
pubmed: 17720802
Neurobiol Dis. 2004 Oct;17(1):10-20
pubmed: 15350961
Behav Processes. 2017 Sep;142:8-20
pubmed: 28532665
JCI Insight. 2020 Mar 26;5(6):
pubmed: 32213706
J Vis Exp. 2018 Nov 20;(141):
pubmed: 30531711
FEBS Lett. 2013 Jun 27;587(13):2046-54
pubmed: 23684647
Molecules. 2015 Oct 07;20(10):18168-84
pubmed: 26457695
J Comp Neurol. 2000 Jul 10;422(4):594-611
pubmed: 10861528
J Clin Exp Neuropsychol. 1985 Oct;7(5):486-96
pubmed: 4066905
J Neurochem. 1996 Nov;67(5):1882-96
pubmed: 8863493
Balkan J Med Genet. 2013 Jun;16(1):21-30
pubmed: 24265581
Arch Neurol. 1997 May;54(5):641-4
pubmed: 9152122
Ann Neurol. 2014 Sep;76(3):403-11
pubmed: 25043804
Acta Neuropathol. 2015 Jan;129(1):1-19
pubmed: 25287911
Neuromuscul Disord. 2020 May;30(5):368-388
pubmed: 32360405
Dev Med Child Neurol. 2016 Jan;58(1):77-84
pubmed: 26365034
Nat Med. 1995 Aug;1(8):829-32
pubmed: 7585189
Annu Rev Med. 2019 Jan 27;70:239-255
pubmed: 30379597
Behav Genet. 1995 Nov;25(6):569-79
pubmed: 8540895
Dev Med Child Neurol. 2001 Jul;43(7):497-501
pubmed: 11463183
Anal Biochem. 1985 Oct;150(1):76-85
pubmed: 3843705
J Neurosci. 2007 Jul 18;27(29):7817-26
pubmed: 17634375
Neuromuscul Disord. 1991;1(2):121-3
pubmed: 1822782